Published in J Clin Virol on April 17, 2009
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
Minority variants of drug-resistant HIV. J Infect Dis (2010) 1.44
Clinical implications of HIV-1 minority variants. Clin Infect Dis (2013) 1.09
Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS One (2011) 0.98
Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLoS One (2011) 0.93
Improved detection of rare HIV-1 variants using 454 pyrosequencing. PLoS One (2013) 0.91
Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PLoS One (2011) 0.89
The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients. PLoS One (2013) 0.87
Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients. AIDS (2014) 0.83
Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection. PLoS One (2011) 0.80
HIV prevalence and route of transmission in Turkish immigrants living in North-Rhine Westphalia, Germany. Med Microbiol Immunol (2011) 0.78
Quantifying Next Generation Sequencing Sample Pre-Processing Bias in HIV-1 Complete Genome Sequencing. Viruses (2016) 0.76
Low-frequency NNRTI-resistant HIV-1 variants and relationship to mutational load in antiretroviral-naïve subjects. Viruses (2014) 0.76
Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation. J Clin Microbiol (2016) 0.75
Minority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCR. PLoS One (2014) 0.75
Quasispecies Analyses of the HIV-1 Near-full-length Genome With Illumina MiSeq. Front Microbiol (2015) 0.75
Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol (2007) 3.64
Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci U S A (2002) 3.46
Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer (2007) 2.75
Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther (2007) 2.49
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med (2014) 2.39
Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res (2003) 2.37
Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol (2003) 2.26
Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol (2008) 1.98
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A (2013) 1.85
Learning multiple evolutionary pathways from cross-sectional data. J Comput Biol (2005) 1.74
Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr (2006) 1.53
HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. Clin Infect Dis (2013) 1.49
Mtreemix: a software package for learning and using mixture models of mutagenetic trees. Bioinformatics (2005) 1.41
Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther (2006) 1.37
Evolution of raltegravir resistance during therapy. J Antimicrob Chemother (2009) 1.33
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res (2009) 1.32
Backbone rigidity and static presentation of guanidinium groups increases cellular uptake of arginine-rich cell-penetrating peptides. Nat Commun (2011) 1.30
Predicting Bevirimat resistance of HIV-1 from genotype. BMC Bioinformatics (2010) 1.30
Prediction of co-receptor usage of HIV-1 from genotype. PLoS Comput Biol (2010) 1.29
Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics (2005) 1.27
Severe human bocavirus infection, Germany. Emerg Infect Dis (2011) 1.27
Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study. J Clin Microbiol (2013) 1.25
Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients. J Clin Virol (2010) 1.23
Severe pneumonia and human bocavirus in adult. Emerg Infect Dis (2006) 1.22
Structures of the Common Cyclodextrins and Their Larger Analogues-Beyond the Doughnut. Chem Rev (1998) 1.20
Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis (2005) 1.19
Detection of bocavirus DNA in nasopharyngeal aspirates of a child with bronchiolitis. J Infect (2006) 1.18
Characterization of methicillin-resistant Staphylococcus spp. carrying the mecC gene, isolated from wildlife. J Antimicrob Chemother (2013) 1.17
Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. Antivir Ther (2007) 1.17
Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival. Adv Otorhinolaryngol (2005) 1.16
Tenofovir resistance and resensitization. Antimicrob Agents Chemother (2003) 1.10
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol (2003) 1.09
Human papillomavirus-positive tonsillar carcinomas: a different tumor entity? Med Microbiol Immunol (2002) 1.08
Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database. J Infect Dis (2009) 1.07
Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy. PLoS One (2008) 1.07
Extraction of viral nucleic acids: comparison of five automated nucleic acid extraction platforms. J Clin Virol (2012) 1.07
Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res (2010) 1.06
Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother (2007) 1.06
Evidence for the association of human papillomavirus infection and cutaneous squamous cell carcinoma in immunocompetent individuals. Arch Dermatol (2003) 1.06
Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J Gen Virol (2009) 1.04
Selecting anti-HIV therapies based on a variety of genomic and clinical factors. Bioinformatics (2008) 1.03
Methods for optimizing antiviral combination therapies. Bioinformatics (2003) 1.02
Sonic hedgehog shedding results in functional activation of the solubilized protein. Dev Cell (2011) 1.02
The E7 protein of cutaneous human papillomavirus type 8 causes invasion of human keratinocytes into the dermis in organotypic cultures of skin. Cancer Res (2005) 1.01
CD8+ T-cell response promotes evolution of hepatitis C virus nonstructural proteins. Gastroenterology (2011) 1.01
The Papillomavirus E2 protein binds to and synergizes with C/EBP factors involved in keratinocyte differentiation. J Virol (2003) 1.01
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother (2011) 1.01
AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood (2005) 1.00
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS (2004) 1.00
Screening for disulfide bonds in proteins by MALDI in-source decay and LIFT-TOF/TOF-MS. Anal Chem (2002) 1.00
The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. Antiviral Res (2012) 1.00
Psychomotor slowing in hepatitis C and HIV infection. J Acquir Immune Defic Syndr (2004) 0.99
When and how to use maraviroc in HIV-infected patients. AIDS (2009) 0.99
Rpd3-dependent boundary formation at telomeres by removal of Sir2 substrate. Proc Natl Acad Sci U S A (2010) 0.99
Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis. BMC Med Inform Decis Mak (2011) 0.99
Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. Antiviral Res (2010) 0.99
Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. PLoS One (2010) 0.98
HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology (2012) 0.97
Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products. J Gen Virol (2005) 0.97
Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol (2006) 0.97
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis (2013) 0.94
High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. AIDS (2010) 0.94
SearchXLinks. A program for the identification of disulfide bonds in proteins from mass spectra. Anal Chem (2006) 0.94
Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients. J Infect (2008) 0.94
Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis. Cancer Res (2013) 0.93
Predicting response to antiretroviral treatment by machine learning: the EuResist project. Intervirology (2012) 0.93
RegaDB: community-driven data management and analysis for infectious diseases. Bioinformatics (2013) 0.93
Novel algorithm for non-invasive assessment of fibrosis in NAFLD. PLoS One (2013) 0.93
Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul. Med Microbiol Immunol (2013) 0.93
Basics of the virology of HIV-1 and its replication. J Clin Virol (2005) 0.93
Structure of HIV-1 quasi-species as early indicator for switches of co-receptor tropism. AIDS Res Ther (2010) 0.93
Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer. J Thorac Oncol (2015) 0.92
Improved prediction of HIV‐1 coreceptor usage with sequence information from the second hypervariable loop of gp120. J Infect Dis (2010) 0.92
Interpol: An R package for preprocessing of protein sequences. BioData Min (2011) 0.92
Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia. Psychiatr Genet (2004) 0.92
Machine learning on normalized protein sequences. BMC Res Notes (2011) 0.92
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther (2010) 0.91
Nintedanib: from discovery to the clinic. J Med Chem (2015) 0.91
Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. J Virol (2010) 0.91
Microfluidic biochip for chemiluminescent detection of allergen-specific antibodies. Biosens Bioelectron (2008) 0.91
Alternative proteolytic processing of hepatocyte growth factor during wound repair. Am J Pathol (2009) 0.91
Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level. Clin Vaccine Immunol (2007) 0.90
The imprinted NPAP1/C15orf2 gene in the Prader-Willi syndrome region encodes a nuclear pore complex associated protein. Hum Mol Genet (2012) 0.89
Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. J Clin Virol (2006) 0.88
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? AIDS Res Ther (2011) 0.88
Improved Bevirimat resistance prediction by combination of structural and sequence-based classifiers. BioData Min (2011) 0.88